Inflammation in the cystic fibrosis lung

Cystic Fibrosis

Volumn , Issue , 2016, Pages 57-77

  Chmiel, James F ^a   Konstan, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84936847453     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (115)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. State of the art. Am J Respir Crit Care Med 1996; 154:1229-1256.
2. Chmiel JF, Konstan MW, Berger M. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27.
3. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003; 4:8-21.
4. Hendry J, Elborn JS, Nixon L, et al. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J 1999; 14:435-438.
5. Noah TL, Black HR, Cheng PW, et al. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997; 175:638-647.
6. Muhlebach MS, Stewart PW, Leigh MW, et al. Quantitation of inflammatory response to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160:186-191.
7. Bedrossian CW, Greenberg SD, Singer DB, et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976; 7:195-204.
8. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197-1204.
9. Birrer P, McElvaney NG, Rüdeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150:207-213.
10. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152:2111-2118.
11. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075-1082.
12. Kirchner KK, Wagener JS, Khan TZ, et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1426-1429.
13. Konstan MW, Walenga RW, Hilliard KA, et al. Leukotriene B4 is markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993; 148:896-901.
14. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150:448-454.
15. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310:1571-1572.
16. Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20:63-70.
17. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104:72-78.
18. Auerbach HS, Williams M, Kirkpatrick JA, et al HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686-688.
19. Eigen H, Rosenstein BJ, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126:515-523.
20. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-854.
21. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990; 141:186-192.
22. Chmiel JF, Konstan MW, Knesebeck JE, et al. IL-10 attenuates excessive inflammation in chronic pseudomonas infection in mice. Am J Respir Crit Care Med 1999; 160:2040-2047.
23. van Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100:2810-2815.
24. Gosselin D, Stevenson MM, Cowley EA, et al. Impaired ability of CFTR knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998; 157:1253-1262.
25. Chmiel JF, Konstan MW, Berger M. Murine models of CF infection and inflammation. In: Skach WR, ed. Methods in Molecular Medicine: Cystic Fibrosis Methods and Protocols. Totowa, NJ: The Humana Press Inc, 2002; 70:495-515.
26. Amadori A, Antonelli A, Balteri I, et al. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009; 103:407-413.
27. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-139.
28. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37:400-406.
29. Fick RB Jr., Robbins RA, Squier SU, et al. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res 1986; 20:1258-1268.
30. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenic role of leukotriene B4. Lancet 1993; 342:465-469.
31. Richman-Eisenstat JB, Jorens PG, Hebert CA, et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264:L413-L418.
32. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90:1296-1301.
33. DiMango E, Zar HJ, Bryan R, et al. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995; 96:2204-2210.
34. Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in human bronchial epithelial cell line. J Clin Invest 1992; 89:1478-1484.
35. Massion PP, Inoue H, Richman-Eisenstat J, et al. Novel pseudomonas product stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest 1994; 93:26-32.
36. Kube D, Sontich U, Fletcher D, et al. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280:L493-L502.
37. Tirouvanziam R, de Bentzmann S, Hubeau C, et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000; 23:121-127.
38. Tabary O, Zahm JM, Hinnrasky J, et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998; 153:921-930.
39. Cromwell O, Walport MJ, Morris HR, et al. Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet 1981; 2:164-165.
40. Zakrzewski JT, Barnes NC, Costello JF, et al. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136:779-782.
41. Miele L, Cordella-Miele E, Xing M, et al. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol 1997; 16:749-759.
42. 2 by bradykinin in human cystic fibrosis cell lines. Am J Respir Cell Mol Biol 1997; 17:481-490.
43. Rowe SM, Jackson PL, Liu G, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008; 178:822-831.
44. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008; 180:5662-5669.
45. Konstan MW, Davis PB. Pharmacological approach for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002; 54:1409-1423.
46. Hostoffer RW, Krukovets I, Berger M. Enhancement by tumor necrosis factor-alpha of Fc alpha receptor expression and IgA-mediated superoxide generation and killing of Pseudomonas aeruginosa by polymorphonuclear leukocytes. J Infect Dis 1994; 170:82-87.
47. KlebanoffSJ, Vadas MA, Harlan JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136:4220-4225.
48. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9:28-31.
49. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res 2007; 56:221-227.
50. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2007; 292:L519-L528.
51. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175:404-412.
52. Ferretti S, Bonneau O, Dubois GR, et al. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170:2106-2112.
53. Hsu DP, van Heeckeren A, Schlucter M, et al. IL-17 targeted antibody treatment increases the excessive pulmonary inflammation in CF mice. Pediatr Pulmonol 2006; (suppl 29):256.
54. Osika E, Cavaillon JM, Chadelat K, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 1999; 14:339-346.
55. Soltys J, Bonfield T, Chmiel J, et al. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr -/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar Macrophages. J Immunol 2002; 168:1903-1910.
56. Chmiel JF, Konstan MW, Saadane A, et al. Prolonged inflammatory response to acute pseudomonas challenge in IL-10 knockout mice. Am J Respir Crit Care Med 2002; 165:1176-1181.
57. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5:357-358.
58. Starosta V, Ratjen F, Rietschel E, et al. Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J 2006; 28:581-587.
59. Freedman SD, Shea JC, Blanco PG, et al. Fatty acids in cystic fibrosis. Curr Opin Pulm Med 2000; 6:530-532.
60. Freedman SD, Weinstein D, Blanco PG, et al. Characterization of LPS-induced lung inflammation in cftr-/-mice and the effect of docosahexaenoic acid. J Appl Physiol 2002; 92:2169-2176.
61. - secretion. J Surg Res 2003; 110:338-343.
62. Weber AJ, Soong G, Bryan R, et al. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281:L71-L78.
63. Bryan R, Kube D, Perez A, et al. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am J Respir Cell Mol Biol 1998; 19:269-277.
64. Perez A, Issler AC, Cotton CU, et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292:L383-L395.
65. Saadane A, Soltys J, Berger M. Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005; 115:405-411.
66. Saadane A, Soltys J, Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol 2006; 117:1163-1169.
67. DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101:2598-2605.
68. Venkatakrishnan A, Stecenko AA, King G, et al. Exaggerated activation of nuclear factorkappaB and altered IkappaB-beta processing cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 23:396-403.
69. Bonfield TL, Konstan MW, Burfeind P, et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13:257-261.
70. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996; 75:319-322.
71. Grasemann H, Michler E, Wallot M, et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24:173-177.
72. Davis PB, Gupta S, Eastman J, et al. Inhibition of proinflammatory cytokine production by PPARgamma agonists in airway epithelial cells. Pediatr Pulmonol 2003; (suppl 25):268-269.
73. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferators activated receptor gamma in cftr -/-mice. J Cell Physiol 2004; 200:235-244.
74. Green S. PPAR: A mediator of peroxisome proliferators action. Mutat Res 1995; 333:101-109.
75. Vanden Berghe W, Vermeulen L, Delerive P, et al. A paradigm for gene regulation: inflammation, NF-kappaB, and PPAR. Adv Exp Med Biol 2003; 544:181-196.
76. Reynders V, Loitsch S, Steinhauer C, et al. Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res 2006; 7:104.
77. Andersson C, Zaman MM, Jones AB, et al. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros 2008; 7:68-78.
78. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. State of the art. Am J Respir Crit Care Med 2001; 163:1693-1722.
79. Elmer HL, Brady KG, Drumm ML, et al. Nitric oxide-mediated regulation of transepithelial sodium and chloride transport in murine nasal epithelium. Am J Physiol 1999; 276:L466-L473.
80. Mhanna MJ, Ferkol T, Martin RJ, et al. Nitric oxide deficiency contributes to impairment of airway relaxation in cystic fibrosis mice. Am J Respir Cell Mol Biol 2001; 24:621-626.
81. Smith AW, Green J, Eden CE, et al. Nitric oxide-induced potentiation of the killing of Burkholderia cepacia by reactive oxygen species: implications for cystic fibrosis. J Med Microbiol 1999; 48:419-423.
82. Sato Y, Walley KR, Klut ME, et al. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression. Am J Respir Crit Care Med 1999; 159:1469-1476.
83. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102:1200-1207.
84. Steagall WK, Elmer HL, Brady KG, et al. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000; 22:45-50.
85. Meng QH, Springall DR, Bishop AE, et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998; 184:323-331.
86. Zheng S, Erzurum S. Regulation of epithelial reactive oxygen and nitrogen species by inflammatory stimuli. Pediatr Pulmonol 2001; (suppl 12):128-129.
87. 2 and inflammatory cytokine production. PLoS ONE 2008; 3:e3367 [Epub October 10, 2008].
88. Shishodia S, Sethi G, Konopleva M, et al. A synthetic triterpenoid, CDDO-Me, inhibits IKB alpha Kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor KB regulated gene products in human leukemic cells. Clin Cancer Res 2006; 12:1828-1838.
89. Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006; 281:35764-35769.
90. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005; 102:4584-4589.
91. Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDOImidazolide are potent inducers of HO-1 and Nrf2/ARE signaling. Cancer Res 2005; 65: 4789-4798.
92. Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6:154-162.
93. Verhaeghe C, Remouchamps C, Hennuy B, et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol 2007; 73:1982-1994.
94. Li J, Johnson XD, Iazvovskaia S, et al. Signaling intermediates required for NFkB activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2003; 284:L307-L315.
95. Nichols D, Ziady AG, Shank S, et al. Proteomic analysis of the anti-inflammatory effects of CDDO in models of CF pulmonary disease. Pediatr Pulmonol 2007; (suppl 30):293.
96. Escotte S, Tabary O, Dusser D, et al. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-b kinase pathway. Eur Respir J 2003; 21:574-581.
97. Velsor LW, van Heeckeren A, Day BJ. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 2001; 281:L31-L38.
98. Roum JH, Buhl R, McElvaney NG, et al. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993; 75:2419-2424.
99. Schuster A, Ueki I, Nadel JA. Neutrophil elastase stimulates tracheal submucosa gland secretion that is inhibited by ICI 200,355. Am J Physiol 1992; 262:L86-L91.
100. SommerhoffCP, Nadel JA, Basbaum CB, et al. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85:682-689.
101. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine protease effect. Thorax 1984; 39:663-667.
102. Tegner H, Ohlsson K, Toremalm NG, et al. Effect of human leukocyte enzymes on tracheal mucosa and mucociliary activity. Rhinology 1979; 17:199-206.
103. Caldwell RA, Boucher RC, Stutts MJ. Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport. Am J Physiol Lung Cell Mol Physiol 2005; 288:L813-L819.
104. Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989; 84:1302-1313.
105. Tosi MF, Berger M. Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol 1988; 141:2097-2103.
106. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86:300-308.
107. Tosi MF, Zakem H. Surface expression of Fc gamma receptor III (CD 16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments. J Clin Invest 1992; 90:462-470.
108. Ferkol T, Cohn LA, Phillips TE, et al. Targeted delivery of antiprotease to the epithelial surface of human tracheal xenografts. Am J Respir Crit Care Med 2003; 167:1374-1379.
109. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends, and physician attitudes. Chest 1999; 115:1053-1058.
110. Ross KR, Chmiel JF, Konstan MW. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 2009; 11:101-113.
111. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
112. Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferatorsactivated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62:1587-1595.
113. Saleh A, Figarella C, Kammouni W, et al. Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells. Infect Immun 1999; 67:5076-5082.
114. Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:228-230.
115. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; (4):CD001505.